ArticleScientific reports2025
In-silico investigations of bioactive compounds from ginger against Lassa fever virus nucleoprotein.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The Lassa fever virus (LFV) has a nucleoprotein (NP) complexed with deoxythymidine triphosphate (dTTP) that suppresses interferon activity, while also being involved in RNA synthesis, making it an excellent target for anti-LFV therapeutics and vaccines. In this study, we evaluated the anti-LFV potential of four bioactive compounds, shogaol, 6-gingerol, 8-gingerol, and 10-gingerol, in silico against 3MX2. Using standard protocols, we performed molecular docking between these ligands against the active site of the LFV NP, a 300 ns molecular dynamics simulation run, dynamic cross-correlation, principal component analysis (PCA) and eigenvalue rank plots, density functional theory (DFT), and prediction of pharmacokinetics properties. The ligands produced favourable docking affinities that ranged from - 7.4 to - 7.7 kcal/mol. The docking poses revealed the interacting amino acid residues within the active site of the NP 3MX2, implicated in viral RNA synthesis and replication. The poses and ligand interaction analyses revealed the formation of water bridges, hydrogen, ionic and pi-pi stacks bonds. Molecular dynamics simulation revealed the formation of stable complexes, especially for 8-gingerol. The PCA and cross-correlational analyses revealed conformational changes in the complexes and net positive interacting amino acid residues. DFT analysis revealed small energy gaps indicative of reactivity. The ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity), SASA (Solvent Accessible Surface Area), PSA (Polar Surface Area), and MolSA (Molecular Surface Area) evaluations indicate that the ligands are good oral drug candidates. The favourable in silico findings support the anti-LFV potentials of the ligands and warrants further in vivo evaluations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.